DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0259786 A1 Roberts Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0259786 A1 Roberts Et Al US 20110259786A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0259786 A1 Roberts et al. (43) Pub. Date: Oct. 27, 2011 (54) DROXDOPA AND PHARMACEUTICAL Publication Classification COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGA (51) Int. Cl. B65D 69/00 (2006.01) (76) Inventors: Michael J. Roberts, Charlotte, NC (52) U.S. Cl. ........................................................ 2O6/570 (US); Simon Pedder, Fort Mill, SC (US) (57) ABSTRACT (21) Appl. No.: 13/174,827 The present invention provides methods of treating fibromy algia or other diseases or conditions causing widespread pain (22) Filed: Jul. 1, 2011 and/or fatigue. In particular, the invention provides pharma ceutical compositions comprising droxidopa alone, or in Related U.S. Application Data combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment (62) Division of application No. 12/044,680, filed on Mar. can comprise treating, preventing, reducing, or eliminating a 7, 2008, now Pat. No. 8,008,285. variety of symptoms recognized as indicative of fibromyal (60) Provisional application No. 60/894,030, filed on Mar. gia. Such as chronic pain, allodynia, hyperalgesia, fatigue, 9, 2007. sleep disturbance, and depression. Patent Application Publication Oct. 27, 2011 Sheet 2 of 2 US 2011/0259786 A1 Lo cN CN cN N - CN ve (Snou) eu US 2011/0259786 A1 Oct. 27, 2011 DROXDOPA AND PHARMACEUTICAL physically. Many fibromyalgia patients also have an associ COMPOSITION THEREOF FOR THE ated sleep disorder that prevents deep, restful, restorative TREATMENT OF FIBROMYALGA sleep. Studies have documented specific and distinctive abnormalities in the stage 4 deep sleep of fibromyalgia CROSS-REFERENCE TO RELATED patients. During sleep, individuals with fibromyalgia are con APPLICATION stantly interrupted by bursts of awake-like brain activity lim iting the amount of time they spend in deep sleep. Additional 0001. The present application is a division of U.S. Patent symptoms associated with fibromyalgia can include the fol application Ser. No. 12/044,680, filed Mar. 7, 2008, which lowing: irritable bowel and bladder, headaches and claims priority to U.S. Provisional Patent Application No. migraines, restless legs syndrome (periodic limb movement 607894,030, filed Mar. 9, 2007, the disclosures of which are disorder), impaired memory and concentration, skin sensi incorporated herein by reference in their entireties. tivities and rashes, dry eyes and mouth, anxiety, depression, ringing in the ears, dizziness, hypotension, vision problems, FIELD OF THE INVENTION Raynaud's Syndrome, neurological symptoms, and impaired 0002 The present application is directed to the use of coordination, as well as other symptoms. droxidopa, alone or in combination with one or more addi 0007 Currently there are no known diagnostic tests spe tional components, for the treatment of Central Sensitivity cific to fibromyalgia. Accordingly, diagnosis generally arises Syndromes, such as fibromyalgia. from evaluation of patient histories, self-reported symptoms, physical examination, and an accurate manual “tender point' BACKGROUND examination based on the standardized criteria from the 0003 Droxidopa is a known synthetic amino acid precur American College of Rheumatology (ACR). As defined by sor of norepinephrine that is converted directly to norepi ACR guidelines, FMS involves the presence of pain for over nephrine via the action of dopa decarboxylase (DDC). Droxi three months duration in all four quadrants of the body, as dopa is generally used to treat orthostatic hypotension (OH) well as along the spine. In addition, pain is elicited by palpa and can be categorized as an antiparkinsonian agent; how tion in at least 11 out of 18 “tender points'. It is estimated that ever, multiple pharmacological activities have been observed it takes an average of five years for a fibromyalgia patient to with droxidopa, including the following: (1) it is directly get an accurate diagnosis, and many fibromyalgia symptoms converted to 1-norepinephrine by the action of the aromatic overlap with those of other conditions. Moreover, the pres L-amino acid decarboxylase which is widely distributed in a ence of comorbidities (such as rheumatoid arthritis or lupus) living body, and thus has an effect of replenishing norepi does not rule out a fibromyalgia diagnosis. nephrine; (2) it has limited permeability through the blood 0008. The etiology and pathophysiology of fibromyalgia brain barrier into the brain; (3) it specifically recovers nore are unknown; however, it is generally believed to include pinephrine activated nerve functions which have decreased in central nervous system involvement. Most researchers agree the central and peripheral nervous system; and (4) it shows fibromyalgia is a disorder of central processing with neuroen various actions, as norepinephrine, via the adrenaline recep docrine/neurotransmitter dysregulation. Fibromyalgia tors in various tissues. patients often experience pain amplification due to abnormal 0004 Fibromyalgia—also referred to as fibromyalgia sensory processing in the central nervous system. Further syndrome (FMS)—is a chronic pain illness or condition char more, studies show multiple physiological abnormalities in acterized by a generalized heightened perception of sensory fibromyalgia patients, including: increased levels of Sub stimuli and manifested by widespreadaches, pain, and stiff stance P in the spinal cord; low levels of blood flow to the ness in muscles, fascia, and joints, as well as Soft tissue thalamus region of the brain; HPA axis hypofunction; low tenderness. The most common sites of pain include the neck, levels of serotonin and tryptophan; and abnormalities in back, shoulders, pelvic girdle, and hands, but any body part cytokine function. Recent studies indicate the possibility of a can be affected. Patients with fibromyalgia display abnor genetic susceptibility to fibromyalgia. malities in pain perception in the form of both allodynia (pain 0009 Treatment of fibromyalgia is often multi-faceted with innocuous stimulation) and hyperalgesia (increased sen and typically seeks to alleviate the associated symptoms sitivity to painful stimuli). Other symptoms typically include rather than treat the condition itself. Medications, such as general fatigue, sleep disturbances, and depression. analgesics, anti-inflammatories, and muscle relaxants can be 0005 Fibromyalgia is characterized by the presence of beneficial in reducing pain. Antidepressants may also be pre multiple tender points and a constellation of symptoms. The scribed. Complementary therapies include: physical therapy, pain of fibromyalgia is profound, widespread, and chronic therapeutic massage, myofascial release therapy, water and is known to migrate to all parts of the body with varying therapy, light aerobics, diet adjustments, acupressure, appli intensity. Fibromyalgia pain has been described as deep mus cation of heat or cold, acupuncture, yoga, relaxation exer cular aching, throbbing, twitching, stabbing and shooting cises, breathing techniques, aromatherapy, cognitive therapy, pain. Neurological complaints such as numbness, tingling, biofeedback, herbs, nutritional Supplements, and osteopathic and burning are often present and add to the discomfort of the or chiropractic manipulation. One or more of these may be patient. Pain severity and stiffness is often worse in the morn used. ing, and aggravating factors include cold/humid weather, 0010 Despite all of the above approaches for management non-restorative sleep, physical and mental fatigue, excessive offibromyalgia, there remains an ongoing search for effective physical activity, physical inactivity, anxiety, and stress. drug treatment of fibromyalgia. Multiple studies have been 0006 Fatigue associated with fibromyalgia can itself be performed around a wide variety of compounds, and Such debilitating, interfering with even the simplest daily activi studies are further referenced in U.S. Pat. No. 6,610,324, ties. At times, fibromyalgia-associated fatigue can leave the which is incorporated herein by reference. None of the pre patient with a limited ability to function both mentally and viously evaluated drugs have shown particularly useful for US 2011/0259786 A1 Oct. 27, 2011 long-term treatment of fibromyalgia beyond symptomatic tyline, nortriptyline, desipramine, traZodone, Venlafaxine, alleviation, and the need for effective drug treatment offibro dulloxetine, milnacipran, nefopam, bupropion, and combina myalgia persists. tions thereof. 0018. The invention also comprises methods of treating SUMMARY OF THE INVENTION fibromyalgia comprising administering droxidopa in combi 0011. The present invention provides pharmaceutical nation with one or more additional active agents having a compositions useful in the treatment of fibromyalgia or other complimentary activity to the activity of droxidopa. In one conditions falling under the umbrella of Central Sensitivity particular embodiment, the invention provides a method of Syndrome (CSS). The pharmaceutical compositions gener treating fibromyalgia comprising administering a pharma ally comprise droxidopa alone or in combination with one or ceutical composition comprising droxidopa and one or more more further pharmaceutically active compounds. DOPA decarboxylase inhibiting compounds. Preferably, the 0012. In one aspect, the invention provides a method of DOPA decarboxylase inhibiting compounds are selected treating fibromyalgia.
Load more

Recommended publications
  • Studies on Mammalian Histidine Decarboxylase by N
    Brit. J. Pharmacol. (1956), 11, 119. STUDIES ON MAMMALIAN HISTIDINE DECARBOXYLASE BY N. G. WATON* From the Department ofPharmacology, University ofEdinburgh (RECEIVED SEPTEMBER 12, 1955) Histamine is present in most mammalian tissues, occurrence of an enzyme capable of decarboxylating but its mode of formation is still not clear. Accord- histidine in all mammals, as the experiments were ing to Blaschko (1945) there are two main theories: confined to a limited range of mammalian species. (1) Histamine is a vitamin, formed outside the The properties and the distribution in laboratory body by bacterial decarboxylation of dietary animals of mammalian histidine decarboxylase, histidine in the alimentary tract. (2) Histamine is a together with the distribution of histaminase and metabolite, formed from circulating histidine by histamine, have been reinvestigated in the hope of the histidine decarboxylase present in some tissues clarifying our knowledge of the role of histamine in of the body. the organism. That bacteria form histamine by decarboxylation METHODS of histidine is well known (Ackermann, 1910, 1911; Formation of Histamine from Histidine by Mammalian Berthelot and Bertrand, 1912; Mellanby and Twort, Tissues 1912; Kendall and Gebauer, 1930; Matsuda, 1933; Rabbit kidneys, which are a rich source of histidine Gale, 1940; Epps, 1945). Gale (1953) showed that decarboxylase, were placed in 0.9% w/v NaCl, freed the bacterial enzyme had several important differen- from all extraneous tissue, cut small and minced in a ces from the other amino acid decarboxylases which Latapie mincing machine. Where a tissue extract was had been studied. required, the minced kidney was ground for 10 min.
    [Show full text]
  • The Effects of Phenelzine and Other Monoamine Oxidase Inhibitor
    British Journal of Phammcology (1995) 114. 837-845 B 1995 Stockton Press All rights reserved 0007-1188/95 $9.00 The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver 12 imidazoline-preferring receptors Regina Alemany, Gabriel Olmos & 'Jesu's A. Garcia-Sevilla Laboratory of Neuropharmacology, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, E-07071 Palma de Mallorca, Spain 1 The binding of [3H]-idazoxan in the presence of 106 M (-)-adrenaline was used to quantitate 12 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irre- versible and reversible monoamine oxidase (MAO) inhibitors. 2 Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-', i.p.), isocarboxazid (10 mg kg-', i.p.), clorgyline (3 mg kg-', i.p.) and tranylcypromine (10mg kg-', i.p.) markedly decreased (21-71%) the density of 12 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-', i.p.) or chlordimeform (10 mg kg-', i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-', i.p.) did not alter the density of 12 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3 In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform dis- placed the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites.
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]
  • Nialamide; SOCIETIES and LECTURES CORRECTION
    414 BRITISH MEDICAL JOURNAL 15 MAY 1971 care, and administration of health services. A. Clements, P. A. Connell, Patricia A. Crawford, G. A. Cupper, M. R. Dean, L. L. Dom- "It is, in short, medicine applied to a group SOCIETIES AND LECTURES bey, D. P. De Bono, J. P. Delamere, Gil- than to an individual patient." The lean P. Duncan, D. B. Dunger, C. E. G. Farqu- rather Br Med J: first published as 10.1136/bmj.2.5758.414 on 15 May 1971. Downloaded from statement adds that it is hoped that the pro- For attending lectures marked * a fee is charged or harson, Pamela C. Fenney, Daphne C. Fielding, a ticket is required. Applications should be made I. R. Fletcher, M. S. Fletcher, Po-Kai Fok, G. J. visional Faculty will be in a position to re- Frost, R. M. Galbraith, Elizabeth A. S. Galvin, first to the institution concerned. D. J. Giraldi, Jenifer I. Glover, B. A. Greenway, ceive applications from those wishing to be- Mary Griffin, J. F. Hamlyn, M. H. Hampton, come founder members later in the year. Monday, 17 May G. P. Harris, P. B. Harvey, A. C. Hillyard, Gillian M. M. Hodge, N. Holmes, Sheilagh M. Further announcements will be made. ABERDEEN UNIVERSITY.-At Medical Buildings, Hope, C. C. Hugh, Joanna E. Ide, Alison Ironside, Foresterhill, 5.30 p.m., dentj centennial lecture Keatley E. James, W. J. Jarrett, Celia A. Jenkins, by Sir Robert Bradlaw: Pigmentation. J. R. Jenner, P. D. Jones, C. L. Kennedy, N. D. Monoamine-oxidase Inhibitors INSTITUTE OF DERMATOLOGY.-4.30 p.m., Mr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • The Effect of Antidepressive Drugs and Some Related Compounds on the Levels of Adenine Nucleotides, Inorganic Phosphate and Phosphocreatine in the Rat Brain by J
    Brit. J. Pharmacol. (1963), 20, 462-470. THE EFFECT OF ANTIDEPRESSIVE DRUGS AND SOME RELATED COMPOUNDS ON THE LEVELS OF ADENINE NUCLEOTIDES, INORGANIC PHOSPHATE AND PHOSPHOCREATINE IN THE RAT BRAIN BY J. J. LEWIS AND G. R. VAN PETTEN From the Experimental Pharmacology Division, Institute of Physiology, University of Glasgow (Received January 11, 1963) The effects upon levels of adenine nucleotides, phosphocreatine and inorganic phosphate of iproniazid, isoniazid, phenelzine, pheniprazine, tranylcypromine, harmine, imipramine, amitriptyline, orphenadrine, diphenhydramine and cocaine have been studied. With the exception of harmine and diphenhydramine, each of these compounds increased the brain level of adenosine triphosphate and, with the exception of imipramine and cocaine, the level of adenosine diphosphate decreased. Harmine had no effect on levels of adenine nucleotides and, in the case of diphenhydramine, the level of adenosine diphosphate increased and the level of adenosine triphosphate tended to decrease. There appears to be a relationship between the ability of the drugs to cause behavioural signs of central nervous stimulation and to produce an increase in the adenosine triphosphate/diphosphate ratio. This effect may be a factor in the action of antidepressive drugs. Many attempts have been made to explain the mechanism of action of anti- depressive drugs on the basis of their ability to inhibit monoamine oxidase, and thereby to increase the effective concentrations in the brain of its substrates, nor- adrenaline and 5-hydroxytryptamine, which have been postulated to act there as transmitters. Major difficulties arise, however, when an attempt is made to correlate the increase in the brain level of a particular amine produced by a drug with its antidepressive activity.
    [Show full text]
  • FIRST of 2 PARTS Web Video at Currentpsychiatry.Com Dr
    FIRST OF 2 PARTS Web video at CurrentPsychiatry.com Dr. Meyer: What to tell patients about diet and monoamine oxidase inhibitors A concise guide to monoamine oxidase inhibitors A better understanding of the risks can lead to increased use of these highly effective agents Jonathan M. Meyer, MD espite an abundance of evidenced-based literature supporting Psychopharmacology Consultant monoamine oxidase inhibitors (MAOIs) as an effective treat- California Department of State Hospitals Sacramento, California Dment for depression, use of these agents has decreased drasti- Assistant Clinical Professor of Psychiatry cally in the past 3 decades. A lack of industry support and the ease of University of California, San Diego use of other agents are contributing factors, but the biggest impedi- San Diego, California Deputy Editor, CURRENT PSYCHIATRY ments to routine use of MAOIs are unfamiliarity with their efficacy Disclosure advantages and concerns about adverse effects, particularly the risk Dr. Meyer is a consultant to Acadia Pharmaceuticals, of hypertensive crises and serotonin syndrome. Many misconceptions Neurocrine Biosciences, Inc., and Teva Pharmaceutical regarding these medications are based on outdated data and studies Industries; and is a speaker for Acadia Pharmaceuticals, Alkermes, Allergan, Merck, Neurocrine Biosciences, Inc., that are no longer reliable. Otsuka America, Inc., Sunovion Pharmaceuticals, and The goal of this 2-part review is to provide clinicians with updated Teva Pharmaceutical Industries. information regarding MAOIs. Part 1 provides a brief description of: • the pharmacology of nonselective irreversible MAOIs • the mechanism by which tyramine induces hypertension • sources of clinically significant tyramine exposure • what to tell patients about dietary restrictions and MAOIs. Part 2 of this guide will cover the risk of serotonin syndrome when MAOIs are combined with inhibitors of serotonin reuptake, how to initi- ate MAOI therapy, and augmenting MAOIs with other agents.
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, and Relevance to Endogenous N,N-Dimethyltryptamines
    ______________________________________________________________________________________________www.neip.info AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 ______________________________________________________________________________________________www.neip.info Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr. Rick Strassman MD and the Cottonwood Research Foundation for helping me find and navigate this path. We acknowledge and are grateful for the collaborative research efforts and dedication of Dr. Jordi Riba and his lab which obtained the human urine and blood samples necessary for the included studies. We wish to dedicate this work to the memory of our friend and colleague, Dr. Manel J. Barbanoj. We acknowledge Dr. Leanna Standish for her diligent work in bringing ayahuasca towards clinical trials and collaborative efforts in supplying our lab with ayahuasca samples. We thank Dr. Dave E. Nichols, Dr. Laurent Micouin and Dr. Simon D. Brandt for generously providing analytical compounds. We thank Connie David, Izabela Lomnicka, Pam Waller and Marian Waguespack for technical support in lab.
    [Show full text]
  • 1.3.1 SPC, Labelling and Package Leaflet MARKETING
    1.3.1 SPC, Labelling and Package Leaflet SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluoxetine Aurobindo 20 mg capsules, hard Fluoxetine Aurobindo 60 mg capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 22.357 mg fluoxetine hydrochloride equivalent to 20 mg of Fluoxetine. Each hard capsule contains 67.072 mg fluoxetine hydrochloride equivalent to 60 mg of Fluoxetine For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule, hard. Fluoxetine Aurobindo 20 mg capsules, hard: Opaque green cap/yellow body, size “4” hard gelatin capsule filled with white to off-white powder and imprinted with ‘J’ on opaque green cap and ‘96’ on yellow body with black ink. Fluoxetine Aurobindo 60 mg capsules, hard: Opaque green cap/yellow body, size “1” hard gelatin capsule filled with white to off-white powder and imprinted with ‘J’ on opaque green cap and ‘95’ on yellow body with black ink. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Adults: Major depressive episodes. Obsessive-compulsive disorder. Bulimia nervosa: Fluoxetine is indicated as a complement of psychotherapy for the reduction of binge- eating and purging activity. Children and adolescents aged 8 years and above: Moderate to severe major depressive episode, if depression is unresponsive to psychological therapy after 4–6 sessions. Antidepressant medication should be offered to a child or young person with moderate to severe depression only in combination with a concurrent psychological therapy. 4.2 Posology and method of administration Posology MARKETING AUTHORISATION APPLICATION Fluoxetine Aurobindo 20 mg capsules, hard– 1.3.1 1.3.1 SPC, Labelling and Package Leaflet Major depressive episodes Adults and the elderly: The recommended dose is 20mg daily.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Radical Remedies
    spring books themselves in the original texts. Quite apart inhibitors (MAOI) quickly fell out of favour Y from his scientific skills, Cuvier was also a because of their associated cardiovascular AR remarkable writer. Eager to convince, he had hazards (the ‘wine-and-cheese’ effect), they O LIBR T an accurate, clear, elegant style and a great had a major impact as the first effective anti- HO sense of drama that allowed him to draw depressants in the United States. Kline was striking and even sometimes dramatic por- instrumental in lobbying Congress for traits of vanished worlds. funds to support psychopharmacology Throughout this book, Rudwick reveals research and by the mid-1960s he had the interest that can be found in reading the appeared on the cover of Fortune magazine texts written by a man of science whose ideas and had become one of the ten best known 8 JOHN GREIM/SCIENCE P and concepts deeply influenced nineteenth men in America. century society and who helped to raise the The MAOI were soon followed by international status of anatomy and geology amitriptyline, developed by the American as professions. company Merck and like imipramine Philippe Taquet is in the Laboratoire de because it chemically resembled chlor- Paléontologie, Muséum National d’Histoire promazine. The American psychiatrist Naturelle, 8, rue de Buffon, 75005, Paris, France. Frank Ayd, however, had heard about Kuhn’s e-mail: [email protected] results with imipramine and persuaded Merck to do trials in depression, which proved successful. Ayd also published an Superpill: Prozac-takers felt “better than well”. influential book on how to diagnose depres- Radical remedies sion in general psychiatric practice, which The “monoamine era” was heralded by the The Antidepressant Era helped to make amitriptyline the first anti- early discovery that reserpine acted by by David Healey depressant with major sales.
    [Show full text]